ImCheck Appoints Stephan Braun as Chief Medical Officer
July 09, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Appoints Stephan Braun as Chief Medical Officer Marseille, France, July 09, 2024 – ImCheck Therapeutics announced today the appointment of Stephan Braun, M.D., Ph.D., as Chief...
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
May 30, 2024 08:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
November 11, 2022 10:12 ET
|
ImCheck Therapeutics SAS
Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors Marseille, France,...
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
June 13, 2022 01:00 ET
|
ImCheck Therapeutics SAS
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
November 12, 2021 14:20 ET
|
ImCheck Therapeutics SAS
Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01...
ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
October 20, 2021 14:21 ET
|
ImCheck Therapeutics SAS
ImCheck Publishes Comprehensive Overview of the DevelopmentResults of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cellsin Science Translational Medicine ...
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
April 09, 2021 00:01 ET
|
ImCheck Therapeutics SAS
ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an expanded immune system activationIncreased densities of activated and proliferating γδ,...
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
March 26, 2020 06:00 ET
|
ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors -- Marseille, France, March 26, 2020 –...